Eli Lilly and Company (BMV:LLY)

Market Cap	16.07T +12.4%
Revenue (ttm)	1.17T +44.7%
Net Income	371.59B +94.9%
EPS	413.17 +96.0%
Shares Out	n/a
PE Ratio	43.26
Forward PE	30.07
Dividend	115.58 (0.63%)
Ex-Dividend Date	Nov 14, 2025

Volume	55
Average Volume	671
Open	18,312
Previous Close	18,231
Day's Range	18,312 - 18,312
52-Week Range	11,630 - 20,340
Beta	0.35
RSI	49.40
Earnings Date	Feb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.

Financial numbers in USD